Nektar Therapeutics (NKTR) Bullish View Reiterated at Aegis Capital as Adynovate Receives Expanded Indications

Aegis Capital analyst Difei Yang reiterated a Buy rating and $21 price target on Nektar Therapeutics (NASDAQ: NKTR) after Shire announced
yesterday that additional indications were approved for Adynovate by the FDA. The new indications include treatment of pediatric patients aged 12 and under, and use in surgical settings for all ages with approval.

"We view this as incrementally positive for the company," Yang said.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $12.66 yesterday.

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Day One Biopharmaceuticals' (DAWN) OJEMDA Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
• XOMA (XOMA) Earns $9M Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM